Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

Using Supercomputers to Checkmate Cancer

Unless they’ve had a family member with cancer, most people don’t know that cancer cells mutate rapidly to escape the drugs we use to kill them.  Duke PhD student Marcel Frenkel knows this problem well,…

Read More

‘Tumour Monorail’ on Fast Track for Human Trials

Pioneering device for treating cancers lures tumour cells out of the brain Pied Piper-style. A biomedical device designed to lure tumour cells out of the brain Pied Piper-style has been awarded specialist breakthrough status by…

Read More

Showcasing Innovation at 2nd “Invented at Duke” Celebration

From Antiperspirant Lotion To Waste Treatment To Targeted Radiotherapy – Duke Made Yet Another Exhibition Of Ingenious Innovations That Span Numerous Fields And Applications. Riding on the success of the first “Invented at Duke” event…

Read More

Duke Celebrates Innovation & Entrepreneurship at 1st Annual “Invented at Duke”

“Commercialization turns discovery into invention, enabling Duke researchers to fulfill our institution’s mission of bringing knowledge to bear in service to society.” –President Price A puncture-proof vascular graft, silicone microspheres, improved eye disease imaging, a…

Read More

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

Agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries DURHAM, N.C.–(BUSINESS WIRE), December 7, 2021–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have…

Read More

Medical Innovation Challenge

Join the world’s largest medical innovation accelerator program and $50K prize program! Align with leading medtech consortia representing over $20 billion in health technology contracting authority. This challenge is the first in a series of…

Read More

Duke Signed a License Agreement with Splendo Health

Duke University and Splendo Health have entered into a license agreement. The Dutch digital health startup is a collaboration between Duke University and Splendo Consulting. Splendo Health has developed SplendoFit, a comprehensive digital platform with…

Read More

Menarini Group, Radius Health Announce License Agreement for Elacestrant

– Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development – Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline…

Read More

PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Full Results from Phase 1 Clinical Trial of PB2452

Read More